EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock jumped 7.61% on Friday to $6.65 against a previous-day closing price of $6.18. With 0.94 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.51 million shares. The 52-week range on EYPT shows that it touched its highest point at $15.63 and its lowest point at $2.19 during that stretch. It currently has a 1-year price target of $30.12. Beta for the stock currently stands at 1.27.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EYPT was up-trending over the past week, with a rise of 3.91%, but this was down by -11.33% over a month. Three-month performance dropped to -56.71% while six-month performance rose 2.31%. The stock gained 62.59% in the past year, while it has gained 90.00% so far this year. A look at the trailing 12-month EPS for EYPT yields -2.67 with Next year EPS estimates of -1.90. For the next quarter, that number is -0.51. This implies an EPS growth rate of 26.48% for this year and 5.52% for next year.
Float and Shares Shorts:
At present, 34.08 million EYPT shares are outstanding with a float of 27.98 million shares on hand for trading. On Oct 30, 2023, short shares totaled 5.35 million, which was 15.14% higher than short shares on Sep 28, 2023. In addition to Dr. Jay S. Duker M.D. as the firm’s President, CEO & Director, Mr. Michael Pine serves as its Chief Business Officer.
Other institutions hold 59.46% of EYPT, in contrast to 24.91% held by mutual funds. Shares owned by individuals account for 19.38%. As the largest shareholder in EYPT with 11.64% of the stake, Franklin Advisers, Inc. holds 4,110,419 shares worth 4,110,419. A second-largest stockholder of EYPT, Suvretta Capital Management LLC, holds 3,492,147 shares, controlling over 9.89% of the firm’s shares. RA Capital Management LP is the third largest shareholder in EYPT, holding 3,370,506 shares or 9.55% stake. With a 4.77% stake in EYPT, the FTIF SICAV – Biotechnology Discov is the largest stakeholder. A total of 1,685,817 shares are owned by the mutual fund manager. The Franklin Small Cap Growth Fund, which owns about 4.17% of EYPT stock, is the second-largest Mutual Fund holder. It holds 1,471,000 shares valued at 8.86 million. Vanguard Total Stock Market ETF holds 2.52% of the stake in EYPT, owning 890,209 shares worth 5.36 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EYPT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With EYPT analysts setting a high price target of $55.00 and a low target of $20.00, the average target price over the next 12 months is $30.13. Based on these targets, EYPT could surge 727.07% to reach the target high and rise by 200.75% to reach the target low. Reaching the average price target will result in a growth of 353.08% from current levels.
Summary of Insider Activity:
Insiders traded EYPT stock several times over the past three months with 0 Buys and 16 Sells. In these transactions, 0 shares were bought while 859,280 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has risen to 23 over the past year. The total number of shares bought during that period was 97,317 while 870,129 shares were sold.